Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials - GBI Research Reports

Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials

Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials - GBI Research Reports
Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials
Published Jan 21, 2011
96 pages — Published Jan 21, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs new report, Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials, provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the effective strategies that shape the industry dynamics. The report also provides comprehensive insight into the clinical trials cost, infrastructure, regulations and key drivers and barriers that impact the clinical trials market in India. Further, the report provides competitive benchmarking for the leading companies that shape the Indian clinical trials market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

The scope of this report includes:
- Annualized data from 2001 to 2009, forecast forward to 2016.
- Market characterization, including market size
- Analysis of the leading therapeutic areas under clinical research in India
- Key drivers and barriers that have a significant impact on the clinical trials market.
- Competitive benchmarking of leading companies.
- Key M&A activities and strategic partnership deals that have taken place in 2009

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers in conducting clinical trial in the country.
- Develop key strategic initiatives by understanding the key focus of clinical research of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

  
Source:
Document ID
GBIHC072MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents36
  List of Tables61
  List of Figures72
Emerging Market for Clinical Trials - India - Introduction91
  GBI Research Report Guidance91
Emerging Market for Clinical Trials - India - Overview1017
  The Clinical Research Process Overview101
    Drug Discovery Phase101
    Pre-Clinical Phase101
    Phase I111
    Phase II111
    Phase III111
    Review and Approval from the Regulatory Agencies111
    Post-marketing Studies111
  Clinical Trial Design and Types111
    Types of Design121
      Parallel Group Trial Design121
      Cross over Trial Design131
      Adaptive Clinical Trial Design142
      Wyeth s Learn &Confirm Model162
  Role of CROs181
  Sponsors of Clinical Trials191
  Intellectual Property Protection in India201
    Patent Act 2005 First Step towards Improving IP Protection201
    Intellectual Property Rights (IPR) Enforcement Rules, 2007201
    Trademarks Bill 2007211
    Drugs and Cosmetics Act (Amendment) 2008211
    Enforcers of Intellectual Property Rights (EIPR) Ensuring IPR Laws Implementation in India211
  The Need for Outsourcing Clinical Trials221
    High Risks and Costs Associated With Drug Development221
    Escalating Costs of Clinical Trials231
    Global Increase in the Number of Clinical Trials Conducted241
    Restructuring the R&D251
    Increased Screening Rates During R&D261
    Expiring Patents Pressurize Pharmaceutical Companies to Reduce Costs261
Emerging Market for Clinical Trials India - Clinical Trial Trends2715
  Registration of Phase l Clinical Trials271
  Registration of Phase ll Clinical Trials281
  Registration of Phase lll Clinical Trials291
  Registration of Phase lV Clinical Trials301
  Clinical Trials Registered in 2009311
  Comparative Analysis of Registered Clinical Trials in BRIC Countries321
  Comparative Analysis of Industry Sponsored Clinical Trials Started in BRIC Countries331
  Comparative Analysis of Population Statistics in BRIC Countries341
    Comparative Analysis of Epidemiology and Prevalence of Major Disease351
      Number of Recruiting Sites for Major Therapeutics in India, Brazil and China352
      Number of Recruiting Sites by Multinational Companies (MNCs) in India, Brazil and China372
      Industry Sponsored Trials Registered with the US Trial Register391
      Local and Multinational Sites Registered With the US Trial Register401
      Number of Sites Involved in Planning, Recruiting, Ongoing and Completed Clinical Trials in India, Brazil and China411
Emerging Market for Clinical Trials India - Market Environment Characterization4221
  Increase in Growth of Global CRO Market will Foster the Growth of Indian Clinical Trial Market421
    Increase in Multinational Sites to Conduct Clinical Trials will Drive the Clinical Trial Market in India431
    Access to a Large Patient Pool442
    Patient Availability for Major Diseases461
      Comparative Analysis of Different Countries for DALY Rate per 1000 Population461
      HIV/AIDS471
      Cardiovascular Diseases481
      Diabetes491
      Cancer501
      Chronic Obstructive Pulmonary Disease (COPD) and Asthma511
    Ethnicity and Genetic Diversity521
    Subject Recruitment and Speed of Trials521
    Cost of Conducting Clinical Trials in India is Approximately 55% of the Cost of Conducting a Clinical Trial in the US521
    Infrastructural Facilities Improve the Clinical Trial Environment531
      Hospitals531
    Facilities for Conducting Clinical Trials541
    Biotechnology Laboratories that Conduct Clinical Trials in India541
      Central Drug Research Institute (CDRI)541
      Institute of Genomics and Integrative Biology (IGIB)541
      Centre for Cellular and Molecular Biology (CCMB)541
      Indian Institute of Chemical Biology (IICB)551
    GLP Approved Facilities in India551
    US FDA Approved New Drug Molecules Being Researched in India561
    Increase in Skilled Pool of Healthcare Professionals571
      Doctors Registered with State Medical Councils571
      Dental Surgeons Registered with State Dental Councils of India581
      Increase in Principal Investigators591
  Market Restraints601
    Lack of Training for Clinical Trial Professionals601
    Quality of Clinical Trial Data601
    ICH GCP Versus Indian GCP601
      Article 39.3 of TRIPS611
    Ethical Issues611
      Illegal and unethical Clinical Trials611
      Slow Hiring in the Government Regulatory Bodies611
    The Need for Proposed Additional Documents for Importing Drugs611
  Clinical Trial Market Size in India621
Emerging Market for Clinical Trials India - Regulatory Landscape6312
  Introduction631
    Drugs and Cosmetics Act631
    The Institutional Ethics Committee (IEC)641
    The Ministry of Health and Family Welfare641
    Central Drug Standard Control Organization (CDSCO)641
    Drug Controller General of India (DCGI)641
    Indian Council of Medical Research (ICMR)651
    Clinical Trials Registry India652
  Clinical Trial Regulation in India672
    Documents Required for Phase l Clinical Trial Application for Molecules Discovered in India692
    Documents Required for Phase l Clinical Trial (Molecules Discovered Outside India)711
    Documents Required for Phase ll Clinical Trial Application711
    Documents Required for Phase lll Clinical Trials721
  Time Frame for Approval721
  Recent Regulatory Changes in Clinical Trials731
    Amended Schedule Y731
    Informed Consent and its Elements731
    Investigator Undertaking741
  Government Incentives741
Emerging Market for Clinical Trials India - CRO Landscape7517
  CRO Locations751
  Service Portfolio and Benchmarking of Indian CROs761
  Acquisitions by Indian CROs771
  CRO Profiles781
    Reliance Life Sciences781
      Business Description781
    Asian Clinical Trials791
      Business Description791
    Diagnosearch Life Sciences801
      Business Description801
    Clininvent811
      Business Description811
    Synchron Research Services Pvt Ltd821
      Business Description821
    Lambda Therapeutic Research Ltd831
      Business Description831
    GVK Biosciences Pvt Ltd841
      Business Description841
    Sristek851
      Business Description851
    Lotus Laboratories Pvt Ltd861
      Business Description861
    Veeda Clinical Research Ltd871
      Business Description871
    Vimta Labs Ltd881
      Business Description881
    Ecron Acunova891
      Business Description891
    SIRO Clinpharm Pvt Ltd901
      Business Description901
    Catalyst Clinical Services911
      Business Description911
Emerging Market for Clinical Trials India - Appendix925
  Market Definitions921
  Abbreviations922
  Research Methodology942
    Coverage941
    Secondary Research941
    Primary Research941
    Expert Panel Validation951
  Contact Us951
  Disclaimer951
  Sources961

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials" Jan 21, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Markets-for-Clinical-Trials-in-India-Favorable-Regulatory-Environment-and-Cost-Effectiveness-Will-Accelerate-the-Number-of-Clinical-Trials-2115-154>
  
APA:
GBI Research Reports. (2011). Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials Jan 21, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Markets-for-Clinical-Trials-in-India-Favorable-Regulatory-Environment-and-Cost-Effectiveness-Will-Accelerate-the-Number-of-Clinical-Trials-2115-154>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.